Answers are grounded in this paper and cite their sources.
Neuroinflammation driven by dysfunctional microglia is a core pathological feature of Alzheimer’s disease (AD), yet most small-molecule therapeutics including α-asarone (α-A) fail to achieve adequate brain exposure because of the blood–brain barrier(BBB) and moreover face dose-limiting hepatotoxicity that collapses the therapeutic window. Here, we devised a temperature-gradient molecular gating strategy that drives α-A into the cavity of recombinant human heavy-chain ferritin (RhFn) without requiring 24-mer disassembly, which compromises the structural integrity and BBB transcytosis efficiency of conventional pH-loaded ferritin. The resulting nanoformulation, α-A@RhFn, exploits transferrin receptor 1 (TfR1)-mediated transcytosis to cross the BBB and deliver α-A to the brain parenchyma at pharmacologically relevant concentrations. Within the brain, α-A@RhFn shifts microglial polarization from the proinflammatory M1 phenotype toward the neuroprotective M2 state by comodulating the TREM2/TLR4 axis, which in turn attenuates neuroinflammation, reduces the amyloid-β (Aβ) burden and protects synaptic integrity. Integrative transcriptomic and metabolomic profiling further revealed that these effects are underpinned by selective activation of the Wnt pathway together with coordinated modulation of cAMP and calcium signaling, collectively reversing gene and metabolite signatures associated with neuroinflammatory and synaptic damage. These multidimensional actions establish a ferritin-based nanomedicine strategy that connects traditional Chinese medicine with precision neurotherapeutics for AD.
No takes yet. Share an insight, caveat, or question.
Z et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: